News und Analysen
Biogen (BIIB) Q3 2023 Earnings Call Transcript
1 Gene Therapy Stock to Buy and Hold for the Long Haul
Biotech companies working on gene therapies have made significant strides lately, but many of them remain relatively risky stocks. Still, gene therapies have the potential to help transform medicine
Why CRISPR Therapeutics Stock Could Be About to Take Off
CRISPR Therapeutics (NASDAQ: CRSP) is a company that doesn't have an approved product on the market. Its operations are unprofitable, and it is burning through cash. There are many reasons that this
Why CRISPR Therapeutics Stock Could Be About to Take Off
CRISPR Therapeutics (NASDAQ: CRSP) is a company that doesn't have an approved product on the market. Its operations are unprofitable, and it is burning through cash. There are many reasons that this
Why CRISPR Therapeutics Stock Could Be About to Take Off
CRISPR Therapeutics (NASDAQ: CRSP) is a company that doesn't have an approved product on the market. Its operations are unprofitable, and it is burning through cash. There are many reasons that this
2 Medical Device Companies Experiencing Strong Demand Even as Weight-Loss Drugs Rise in Popularity
There's a growing fear among investors that weight-loss drugs and treatments such as Ozempic could negatively impact many businesses, from food companies to healthcare businesses. But there are a
2 Medical Device Companies Experiencing Strong Demand Even as Weight-Loss Drugs Rise in Popularity
There's a growing fear among investors that weight-loss drugs and treatments such as Ozempic could negatively impact many businesses, from food companies to healthcare businesses. But there are a
4 Reasons to Worry About Vertex Pharmaceuticals -- Debunked
Some investors might be at least a little more nervous about Vertex Pharmaceuticals (NASDAQ: VRTX) now than they were only a few days ago. Why? The big biopharmaceutical company provided its
4 Reasons to Worry About Vertex Pharmaceuticals -- Debunked
Some investors might be at least a little more nervous about Vertex Pharmaceuticals (NASDAQ: VRTX) now than they were only a few days ago. Why? The big biopharmaceutical company provided its
4 Reasons to Worry About Vertex Pharmaceuticals -- Debunked
Some investors might be at least a little more nervous about Vertex Pharmaceuticals (NASDAQ: VRTX) now than they were only a few days ago. Why? The big biopharmaceutical company provided its
EQS-News: Evotec SE reports results for the first nine months 2023 and provides corporate update
Why Sage Therapeutics Stock Sank Today
It wasn't a wise move for investors to hold or buy Sage Therapeutics (NASDAQ: SAGE) shares on Tuesday. Its price tumbled by nearly 5% as the market digested the healthcare company's third-quarter
Why Coherus Biosciences Stock Dropped Today
Shares of Coherus Biosciences (NASDAQ: CHRS) were down by about 30% as of 3:25 p.m. ET Tuesday after the company announced disappointing third-quarter results and lowered its full-year guidance.
2 Monster Stocks to Buy Without Any Hesitation
While the phrase "monster stocks" might generally have investors thinking of Tesla, Apple, or similar behemoths, the two businesses discussed in this article are sneakily monstrous.
First, consumer
MacroGenics (MGNX) Q3 2023 Earnings Call Transcript
Vertex Pharmaceuticals (VRTX) Q3 2023 Earnings Call Transcript
Vertex Pharmaceuticals (NASDAQ: VRTX)Q3 2023 Earnings CallNov 06, 2023, 4:30 p.m. ET
Operator
Source Fool.com
Vertex Pharmaceuticals (VRTX) Q3 2023 Earnings Call Transcript
Vertex Pharmaceuticals (NASDAQ: VRTX)Q3 2023 Earnings CallNov 06, 2023, 4:30 p.m. ET
Operator
Source Fool.com
Vertex Pharmaceuticals (VRTX) Q3 2023 Earnings Call Transcript
Vertex Pharmaceuticals (NASDAQ: VRTX)Q3 2023 Earnings CallNov 06, 2023, 4:30 p.m. ET
Operator
Source Fool.com
EQS-News: Evotec and Dewpoint Therapeutics enter strategic partnership in oncology
Why Celldex Therapeutics Blasted 13% Higher on Monday
Clinical-stage biotech Celldex Therapeutics (NASDAQ: CLDX) was a standout on the stock market Monday. The company's share price closed a sturdy 13% higher on the day, thanks to freshly published
Axsome Therapeutics (AXSM) Q3 2023 Earnings Call Transcript
Axsome Therapeutics (NASDAQ: AXSM)Q3 2023 Earnings CallNov 06, 2023, 8:00 a.m. ET
Operator
Source Fool.com
3 Spectacular High-Yield Dividend Stocks to Buy in November
Not all dividend stocks are in the same league. Some offer puny yields. Others, though, provide exceptionally high ones plus solid long-term growth prospects.
Three Motley Fool contributors think
1 Under-the-Radar Stock That Could Triple By 2030
Weight-loss medicines are rising in popularity. According to some estimates, this market will be worth $44 billion in risk-adjusted sales by 2030, while it was only valued at $2.5 billion last year
Why Trupanion Stock Soared Today
Shares of Trupanion (NASDAQ: TRUP) rallied as much as 30% early Friday, then settled to trade up 16.7% as of 2:45 p.m. ET after the pet insurance provider announced better-than-expected
Why CRISPR Therapeutics Stock Charged Northward This Week
Gene therapy stocks have been a bright spot in the market this week. For instance, gene correction specialist CRISPR Therapeutics (NASDAQ: CRSP) has so far gained 19.6% through the first four days